Glaucoma Surgery Devices Market Size, Share, Analysis Challenges, and Future Growth Forecast 2023-2032

According to a new report published by K D Market Insights, titled, “Glaucoma Surgery Devices Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global glaucoma surgery devices market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The growing incidence of glaucoma, a chronic eye disease that could cause blindness if left untreated. The growing geriatric populace and the growing cognizance about eye health which are the major factors augmenting the growth of the global glaucoma surgery devices market. The global glaucoma surgery devices market is anticipated to grow at a moderate CAGR of 6.5% from 2023 to 2032. The market's revenue surged to $3.0 billion in 2022, and it is expected to further accelerate, reaching a notable $5.7 billion by 2032.

Glaucoma is one of the leading causes of irreversible blindness, and the growing prevalence of this continual eye ailment, which is further expected to create ample growth opportunities for the global glaucoma surgery devices market during the forecast period i.e., 2023-2032. Moreover, with a higher hazard of developing glaucoma, the aged population is searching for advanced and minimally invasive treatment options, has propelled market expansion. Advancements in surgical strategies and technology, is expected to contribute towards the market growth during the period.

The North America region accounted for the largest share in the global glaucoma surgery devices market in 2022. The region is further projected to continue dominating in the market during the forecast period. This can be attributed to the well-established healthcare infrastructure. Additionally high prevalence of glaucoma, favorable reimbursement policies, and robust research activities.

According to surgery type, the conventional glaucoma surgeries segment accounted for the largest market share in the glaucoma surgery devices market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.

The global glaucoma surgery devices market is segmented into surgery type, product, end-users and region. Based on surgery type, the market is bifurcated into conventional glaucoma surgeries and minimally invasive glaucoma surgeries. Based on product, it is classified into implants & stents, glaucoma drainage devices, and glaucoma laser devices. Based on end-users, it is classified into eye hospital & ophthalmology clinic, ambulatory surgical centers (ASCS), and outpatient surgical centers.

The global glaucoma surgery devices market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).

Key Insights of Glaucoma Surgery Devices Market

On the basis of surgery type, the conventional glaucoma surgeries segment accounted for the largest market share in the glaucoma surgery devices market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
On the basis of region, North America accounted for the largest share in the global glaucoma surgery devices market in 2022. The region is further projected to continue dominating in the market during the forecast period.
On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.

Some of the major glaucoma surgery devices companies profiled in the report include Abbvie Inc. (Allergan), Alcon Inc, Glaukos Corporation, Johnson & Johnson (Abbott Medical Optics), iStar Medical SA, Lumibird Medical (Ellex Medical Lasers Ltd), Lumenis Ltd, New World Medical, Inc., Santen Pharmaceutical Co. Ltd, Topcon Corporation.